Urolithin A Modulates SIRT ‐1 Mediated Improvement of Mitochondrial Health in Experimental Model of Oxaliplatin Induced Peripheral Neuropathy

Oxaliplatin-induced peripheral neuropathy (OIPN) is a major dose-limiting adverse reaction of chemotherapy. It is characterised by motor and sensory hypersensitivity, loss of myelinated nerve fibres, oxidative stress, mitochondrial dysfunction and neuroinflammation. Urolithin A, a bioactive gut metabolite of ellagitannins, is recognised for its ability to restore mitochondrial homeostasis. This study investigated the neuroprotective efficacy of urolithin A against experimental OIPN, focusing on its ability to simultaneously balance mitochondrial biogenesis and mitophagy. To study OIPN, male Sprague-Dawley rats were administered oxaliplatin (4 mg/kg) over a 4-week period, paired with concurrent oral doses of urolithin A (25 and 50 mg/kg). The animals were evaluated through behavioural assays (Von Frey, Hargreaves Plantar and Randall-Selitto, etc.) and functional tests measuring sensory and motor nerve conduction velocity. Oxidative stress markers (MDA and GSH) and mitochondrial dynamics, specifically biogenesis and mitophagy, were measured. In parallel, an in vitro study exposed Neuro2a cells to 50 μM of oxaliplatin, followed by urolithin A treatment (15 μM), to investigate its neuroprotective efficacy and underlying molecular mechanisms. Urolithin A significantly attenuated OIPN, alleviating thermal and mechanical hypersensitivity in behavioural assessments. It mitigated oxidative stress and mitochondrial dysfunction while promoting mitochondrial biogenesis via the SIRT1-mediated pathway both in vitro and in vivo. Simultaneously, urolithin A enhanced mitophagy by directly activating SIRT1-induced autophagy markers, leading to a marked reduction in inflammatory cytokine levels and eventual mitigation of neuropathic pain. Urolithin A protected against oxaliplatin-induced neurotoxicity in Neuro2a cells and reversed peripheral neuropathy in rats by restoring SIRT1-mediated mitochondrial biogenesis and mitophagy balance and maintaining mitochondrial health. These findings highlight urolithin A as a potential therapeutic candidate for OIPN.

Authors

Institutions

Publication Details

Journal
Phytotherapy Research
Published
2026-11-13
DOI
https://doi.org/10.1002/ptr.70506
Primary Topic
Cancer Treatment and Pharmacology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Urolithin A Modulates SIRT ‐1 Mediated Improvement of Mitochondrial Health in Experimental Model of Oxaliplatin Induced Peripheral Neuropathy

Sayani Banerjee, Lokesh Sharan, David Paul, Arka Das et al.
Phytotherapy Research
Cancer Treatment and Pharmacology
article

Urolithin A Modulates SIRT ‐1 Mediated Improvement of Mitochondrial Health in Experimental Model of Oxaliplatin Induced Peripheral Neuropathy

Sayani Banerjee, Lokesh Sharan, David Paul, Arka Das, Anubroto Pal, Sarath Babu V, Sugato Banerjee, Neelanjan Chowdhury, Ravindra Kumar
article en

Abstract

Oxaliplatin-induced peripheral neuropathy (OIPN) is a major dose-limiting adverse reaction of chemotherapy. It is characterised by motor and sensory hypersensitivity, loss of myelinated nerve fibres, oxidative stress, mitochondrial dysfunction and neuroinflammation. Urolithin A, a bioactive gut metabolite of ellagitannins, is recognised for its ability to restore mitochondrial homeostasis. This study investigated the neuroprotective efficacy of urolithin A against experimental OIPN, focusing on its ability to simultaneously balance mitochondrial biogenesis and mitophagy. To study OIPN, male Sprague-Dawley rats were administered oxaliplatin (4 mg/kg) over a 4-week period, paired with concurrent oral doses of urolithin A (25 and 50 mg/kg). The animals were evaluated through behavioural assays (Von Frey, Hargreaves Plantar and Randall-Selitto, etc.) and functional tests measuring sensory and motor nerve conduction velocity. Oxidative stress markers (MDA and GSH) and mitochondrial dynamics, specifically biogenesis and mitophagy, were measured. In parallel, an in vitro study exposed Neuro2a cells to 50 μM of oxaliplatin, followed by urolithin A treatment (15 μM), to investigate its neuroprotective efficacy and underlying molecular mechanisms. Urolithin A significantly attenuated OIPN, alleviating thermal and mechanical hypersensitivity in behavioural assessments. It mitigated oxidative stress and mitochondrial dysfunction while promoting mitochondrial biogenesis via the SIRT1-mediated pathway both in vitro and in vivo. Simultaneously, urolithin A enhanced mitophagy by directly activating SIRT1-induced autophagy markers, leading to a marked reduction in inflammatory cytokine levels and eventual mitigation of neuropathic pain. Urolithin A protected against oxaliplatin-induced neurotoxicity in Neuro2a cells and reversed peripheral neuropathy in rats by restoring SIRT1-mediated mitochondrial biogenesis and mitophagy balance and maintaining mitochondrial health. These findings highlight urolithin A as a potential therapeutic candidate for OIPN.

Phytotherapy Research
National Institute of Pharmaceutical Education and Research (IN)
Cancer Treatment and Pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon